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Abstract
The aim of this study was to analyse the distribution of KIR haplotypes and the KIR2DL2/3 alleles in chronic HCV-infected
patients in order to establish the influence on the response to pegylated interferon plus ribavirin classical treatment. The
alleles study of previously associated KIR2DL2/3 showed that KIR2DL2*001 was more frequent in non-SVR (NSVR) (42.2% vs.
27.5%, p,0.05) and KIR2DL3*001 was associated with sustained viral response (SVR) (41.6% vs. 61.2%, p,0.005). The
KIR2DL3*001-HLA-C1 association was also significant (24.5% vs. 45.7%, p,0.001). From the frequencies of KIR obtained, 35
genotypes were assigned on the basis of previous studies. The centromeric A/A genotype was more frequent in SVR (44.1%
vs. 34.5%, p,0.005) and the centromeric B/B genotype was found to be significantly more frequent in NSVR (20.9% vs.
11.2%, p,0.001). The logic regression model showed the importance of KIR genes in predicting the response to combined
treatment, since the positive predictive value (PPV) was improved (from 55.9% to 75.3%) when the analysis of KIR was
included in addition to the IFNL3 rs12979860 polymorphism. The study of KIR receptors may be a powerful tool for
predicting the combined treatment response in patients with chronic HCV infection in association with the determination of
IFNL3 polymorphism.
Citation: Vidal-Castin˜eira JR, Lo´pez-Va´zquez A, Martı´nez-Borra J, Martı´nez-Camblor P, Prieto J, et al. (2014) Diversity of Killer Cell Immunoglobulin-Like Receptor
(KIR) Genotypes and KIR2DL2/3 Variants in HCV Treatment Outcome. PLoS ONE 9(6): e99426. doi:10.1371/journal.pone.0099426
Editor: Niklas K. Bjo¨rkstro¨m, Karolinska Institutet, Sweden
Received February 19, 2014; Accepted May 14, 2014; Published June 13, 2014
Copyright:  2014 Vidal-Castio´eira et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Supported by Spanish grant PI12-02587 from the Instituto de Salud Carlos III, RETICS REDiNREN (RD12/0021/0021) from the Instituto de Salud Carlos III
and by European Union ‘‘Fondos FEDER ’’. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: inmuno@hca.es
Introduction
Innate immunity is the first line of defence against pathogens,
and operates non-specifically [1]. Natural killer (NK) cells are
important effector lymphocytes that participate in this early
immune response to pathogens, including virally infected cells, and
tumoral cells through the production of cytokines and chemokines
[2]. NK cell function is regulated by a network of activating and
inhibitory receptors [3], including killer immunoglobulin-like
receptors (KIRs) [4].
KIRs, which are members of the CD158 gene family, are
clustered in a 160 kilobase (kb) length of the 19q13.4 chromosome
region within the leukocyte receptor complex (LRC) [5]. This
diverse family of activating and inhibitory receptors modulates the
development and activity of NK cells and some subpopulations of
CD8+ T cells by interacting with the class I major histocompat-
ibility complex (MHC) [6]. Although this recognition is well
established, their interactions have yet to be fully understood.
Genetic analyses indicate that KIR variation, in conjunction with
polymorphic MHC class I genes, plays a key role in immune
defence [7]. Thus, the extensive polymorphisms of HLA and KIR
genes and their independent segregation give rise to unusual
expression features. KIR receptors for which there is no HLA
ligand can be expressed, while conversely an HLA ligand can be
expressed for which there is no KIR. Furthermore, the interactions
are influenced by peptides that bind to HLA class I and are
contacted by KIR [8].
To date, 14 KIR receptors and two pseudogenes have been
identified, and on the basis of this variation in gene content, more
than 50 KIR haplotypes have been identified [9].
Previous analyses of these haplotypes indicate that they are
subdivided into two groups: haplotype A and haplotype B [10].
Group A haplotypes comprise seven genes (KIR2DL1, KIR2DL3,
KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3 and KIR2DS4) and two
pseudogenes (KIR2DP1 and KIR3DP1). The gene KIR2DS4 is
potentially activating but is disabled by a 22-bp frameshift deletion
in approximately 75% of A haplotypes and is only functional in a
minority of individuals [11]. Moreover, KIR2DL4 encodes a
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receptor that has both inhibitory and activating functions [12]. In
contrast, Group B haplotypes are composed of varying numbers of
KIR genes, including at least one of the following KIRs: KIR2DL2,
KIR2DL5, KIR3DS1, KIR2DS1, KIR2DS2, KIR2DS3 and KIR2DS5.
Subsequently, these two groups were shown to have distinct
associations with several diseases [13,14]. Classic linkage disequi-
librium (LD) studies identified two distinct regions in the KIR
cluster around the KIR2DL4 gene: a centromeric (cen) region,
which seems to be driven by the KIR2DL5 and KIR2DL2/3 loci
[15], and a telomeric (tel) region driven by the KIR3DL1/S1 locus
[10].
Several studies have shown that individuals vary in the number
and type of KIR loci they contain [16]. This variability and
biomedical relevance of KIRs make it important to study their
organization. There is increasing evidence that receptor–ligand
specificity between polymorphic KIRs and polymorphic MHC
class I genes is associated with a wide range of infections, such as
HIV and hepatitis C, in addition to autoimmune diseases [17],
disorders in pregnancy [18], and in bone marrow and solid organ
transplantation [19,20,21].
Hepatitis C virus (HCV) is a hepatotropic non-cytopathic
positive-strand RNA virus that is a major cause of chronic
hepatitis, cirrhosis, and hepatocellular carcinoma, affecting over
170 million people worldwide [22]. Pegylated interferon-alpha
(Peg-IFN-a) plus Ribavirin has been the most effective therapy for
chronic hepatitis C [23], until the emergence of new directly
acting antiviral agents (DAA) like Boceprevir and Telaprevir.
Several host and viral factors influence the treatment outcome
[24,25] and approximately 50% of patients with HCV genotype 1
achieve a sustained viral response (SVR) [26]. Recently, single
nucleotide polymorphisms (SNPs) in the IFNL3 gene (Also known
as IL28B) that influence the responsiveness of treatment of HCV
infection and the clearance of HCV have been identified [27,28].
The strongest association has been shown with the IFNL3 SNP
rs12979860 C/C genotype, which has an SVR ratio over 70% in
European-American and Hispanic patients with the HCV
genotype 1 [27]. Other host genetic factors associated with the
response outcome have been reported, such as KIR [29] and the
PD-1.3 polymorphism in the PDCD1 gene, which has recently
been described by our group [30].
The aim of this study was to investigate the role of KIR genes
and their genotypes on the response to combined therapy in a
well-characterised group of patients with chronic HCV infection.
We also examined the effect of the different KIR2DL2/2DL3 alleles
and KIR haplotypes on the response outcome. Finally, a
mathematical model was developed to evaluate the combined
effect of IFNL3 polymorphisms and KIR receptors.
Materials and Methods
Study population
A cohort of 811 unrelated HCV genotype 1 infected Caucasian
patients was recruited from several Spanish Hospitals: Hospital
Universitario Central de Asturias (HUCA), Hospital San Agustı´n
(Aviles), Clı´nica Universitaria de Navarra (CUN) and Hospital La
Princesa (Madrid).
Patients included in this study had received their first course of
antiviral therapy. The duration of treatment with PEG-IFN-a-2a
or a-2b and Ribavirin was established in 48 weeks on the basis of
the HCV genotype, according to consensus clinical guidance.
Those without HCV RNA in their sera by six months post-
treatment were defined as sustained viral responders (SVR,
n = 313). The other patients were defined as non-sustained viral
responders (NSVR, n = 498) which included non-responders,
relapsers and partial responders.
This study was granted ethical approval by the Regional Ethics
Committee for Clinical Investigation of all hospitals (Regional
Ethics Committee of Clinical Research of Principado de Asturias;
Ethics Committee of Clinical Research of Navarra; Regional Ethics
Committee of Clinical Research of Madrid). All participants
provided written informed consent.
DNA extraction
Genomic DNA was extracted from peripheral blood with the
Magtration-MagaZorb DNA Common Kit-200 N using the
Magtration 12GC system (Precision System Science Co., Ltd.,
Woerrstadt, Germany) and the Maxwell 16 Blood Purification Kit
using the Maxwell 16 Instrument (Promega Corporation,
Madison, Wisconsin, USA).
IFNL3 genotyping
The rs12979860 SNP was genotyped by amplifying the region
containing the polymorphic site and hybridisation with fluores-
cent-labelled probes in an RT-PCR based on the melting-curve
analysis using the Light-Cycler system (Roche Diagnostics,
Mannheim, Germany) [30].
HLA/KIR genotyping
The HLA-B, HLA-C, and KIR genes were typed by using
Lifecodes HLA-SSO and KIR-SSO typing kits (Tepnel Lifecodes
Corporation, Stamford, UK) based on the Luminex Multi-Analyte
Profiling system (xMAP technology) (Luminex Corp., Austin, TX),
following the manufacturer’s instructions. Ambiguities in KIR
typing were resolved by PCR-single specific primer (SSP), as
defined previously [31]. HLA-Bw4, HLA-Bw6, HLA-C1 and
HLA-C2 were assigned on the basis of the amino acid residues of
HLA-B and HLA-C alleles [32]. The KIR genotypes were
deduced from KIR profiles as previously described [10,33]. KIR
gene profiles were classified with respect to the centromeric and
telomeric regions of the KIR A and B haplotypes: Cen-A driven
by KIR2DL3 while Cen-B by KIR2DL2. On the other hand the
Tel-A is driven by KIR3DL1 and Tel-B by KIR3DS1.
Finally, a PCR was also designed for KIR2DL5 subtyping to
distinguish between expressed and non-expressed variants of this
gene, as previously described [34].
KIR2DL2 and KIR2DL3 oligotyping
Based on the results of KIR genotyping, patients with KIR2DL2
and/or with KIR2DL3 genes were genotyped as described
elsewhere [35,36] to identify different alleles. 146 NSVR and
103 SVR patients were randomly selected for this study. Different
regions of these KIR receptors were selectively amplified by a
PCR using locus-specific primers. For SSOP hybridisation,
amplified DNA was blotted onto nylon membranes and hybridised
with a panel of 5 and 13 SSOPs designed to detect unique
sequence motifs of known KIR2DL2 and KIR2DL3 alleles,
respectively. Alleles were assigned with respect to the reaction
patterns of the SSOP, based on the known KIR2DL2 and KIR2DL3
sequences. This method identifies the most common alleles for
KIR2DL2 (*001, *002, *003, *004 and *005) and for KIR2DL3
(*001, *002, *003, *004, *005 and *006).
Statistical analysis
Continuous variables were summarised as the mean and
standard deviation. Categorical variables were summarised as
absolute frequencies and percentages. The Genetic Analysis
KIR Genes in Chronic HCV Infected Patients
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Package (GAP) in R (www.r-project.org) was used to compute LD
statistics for pairs of alleles. In particular, the D’ statistic based on
Cramer’s V was used. The general bootstrap algorithm (gBA) [37]
was used to compare global and particular LDs in responders and
non-responders. Fisher’s exact test was used to examine the
relationship between categorical variables. In addition, where the
relationships were statistically significant (p , 0.05) the odds ratios
(ORs) and the respective 95% confidence intervals were also
reported. Finally, the R package LogicReg (available in the
CRAN) was used to develop a logic regression (LR) model [38]. A
stepwise criterion based on the Akaike interaction was included in
this model. LR aims to identify predictors that are Boolean
(logical) combinations of the original predictors. In particular, LR
looks for an optimal model of the form:
logit E Y½ ð Þ~b0zb1:L1zb2:L2z:::zbp:Lp
where Y is the response (Yes/No), b1,…, bp are the parameters,
and L1,…, Lp are Boolean combinations (intersection (AND, ^ ),
unions (OR _ ) and complement (NOT, C) of the dichotomous
variables considered. The Li’s are also called logic trees. Our
model considered the variables: IFNL3 rs12979860 genotype,
KIR2DL2/3, KIR2DL2-HLA, KIR2DL3-HLA, KIR Genotype, KIR
centromeric motif, KIR telomeric motif and KIR2DL2/3 alleles
described in this study. We also included clinical parameters like
viral load, BMI, sex, etc. The logic trees were selected by a greedy
search based on the usual deviance as the measure of model fit.
Finally, the ROC curve and the area under the ROC curve (AUC)
were used to check the quality of the model obtained.
Results
Distribution of KIR receptors frequency
A total of 313 patients (38.4%) with SVR and 498 (61.4%) with
NSVR were recruited for the study. All of them were genotyped
for HLA-B, HLA-C and KIR receptors. As shown in table 1, the
framework genes KIR2DL4, KIR3DL2, KIR3DL3 and the pseudo-
gene KIR3DP1 were present in all individuals. Also, as previously
described [29,39], three KIR genes were associated with chronic
hepatitis C treatment response: KIR2DL2 was more frequent in the
NSVR group (OR = 1.51 95%, CI = 1.13–2.02; p,0.005) while
KIR2DL3 was associated with good treatment outcome
(OR = 0.48, 95% CI = 0.32–0.72; p,0.001). On the other hand,
the activating KIR2DS2 gene was also associated with a poor
response to combined therapy (OR = 1.55, 95% CI = 1.16–2.07;
p,0.005). Moreover, considering KIR2DL2 and KIR2DL3 alleles
of the same locus [15], the differences between the two groups of
patients were statistically significant when they were in the
homozygous state: KIR2DL2/KIR2DL2 with NSVR (20.7% vs.
11.2%, p,0.001) and KIR2DL3/KIR2DL3 with SVR (35.3% vs
45%, p , 0.01). Differences in other KIR receptors studied were
not significant.
Next, we have genotyped for HLA-B and HLA-C alleles but we
did not find statistical differences except for HLA-C*07. We found
that this allele, which belonged to HLA-C1 group, was more
frequent in patients with SVR (2n = 148, 23.6%) than in non
responders (2n = 171, 17.2%) (p,0.005, Table S1).
When the distribution of KIR inhibitory receptors with their
HLA ligands was analysed, we found, as previously described, that
the homozygous KIR2DL3-HLA-C1 genotype was significantly
more common in patients with SVR than in those with NSVR
(OR = 0.34, 95% CI = 0.21–0.54; p,0.001). In contrast,
KIR2DL2-HLA-C1C2 was more frequent in NSVR patients
(OR = 2.85, 95% CI = 1.56–5.26; p,0.001). We also found that
KIR2DL3-HLA-C*07 was significantly associated with a good
treatment outcome (27.3% in NSVR vs 45% in SVR, p,0.001,
table S1).
As expected, with regard to KIR2DS2, we observed an
association of KIR2DS2-HLA-C1 with NSVR (51.2% vs. 40.9%;
p,0.01). No other significant association was found in relation to
KIR2DS2. Finally, we did not find statistical associations between
KIR3DL1/S1+HLA-Bw480I/80T genotypes and treatment out-
come. In fact, KIR3DS1, previously associated with hepatocellular
carcinoma (HCC) progression [40], was also not significant..
Oligotyping of KIR2DL2 and KIR2DL3
Having found an association of KIR2DL2 and KIR2DL3 with
treatment outcome, we decided to analyse the possible influence of
different KIR2DL2/KIR2DL3 alleles in the response to HCV
treatment (Table 2). For KIR2DL2, five alleles were analysed
(KIR2DL2*001-005), but only KIR2DL2*001 and KIR2DL2*003
were identified in our cohort. In the case of KIR2DL3, six alleles
were analysed (KIR2DL3*001-006), with only KIR2DL3*001 and
KIR2DL3*002 being found in our population.
The study of the contribution of these alleles to the treatment
response showed that the KIR2DL2*001 was significantly more
frequent in NSVR (OR = 1.92, 95% CI = 1.11–3.31; p,0.05) and
the KIR2DL3*001 was associated with SVR (OR = 0.44, 95%
CI = 0.26–0.74; p,0.005). Moreover, KIR2DL3*001 in combina-
tion with HLA-C1 ligand was related to a good treatment outcome
(OR = 0.37, 95% CI = 0.22–0.65; p,0.001). No association was
found between KIR2DL3*002-C1, KIR2DL2*001-C1 and
KIR2DL2*003-C1 (data not shown).
KIR haplotype frequency in patients with chronic HCV
infection
In the current study, the KIR genotypes were analysed to
determine the KIR haplotypes, based on those characterised in
other studies [10,33]. Thirty-five genotypes were identified in this
cohort and were resolved into corresponding pairs of haplotypes
(Figure 1).
The most common genotype was KIR3DL3-2DL3-2DP1-2DL1-
3DP1-2DL4-3DL1-2DS4-3DL2 (Genotype Nu 1), corresponding to
homozygosity for the major subtype of the previously reported A
haplotype (28.1% in SVR and 23.5% in NSVR). Most of these
genotypes included the KIR2DL3*001 allele. The other KIR
genotypes found included at least one activating locus in addition to
KIR2DS4, corresponding to haplotype B. These genotypes are named
Bx. In general, we observed that genotypes that included KIR2DL2,
especially the *001 allele, were present at a higher frequency in
NSVR patients. The most prevalent was KIR3DL3-KIR2DS2-
KIR2DL2-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4-3DL2 (geno-
type Nu 2), which includes the KIR2DS2 in strong LD with the
KIR2DL2 gene. On the other hand, in SVR patients, the
predominant genotypes were those that included KIR2DL3, like
the aforementioned genotype 1.
The overall patterns of linkage disequilibrium of KIR receptors
were similar in two groups of patients (Figure 2). As previously
described, the measures showed two distinct regions in the KIR
cluster around the KIR2DL4 gene. One was a centromeric region
(KIR3DL3, KIR2DS2, KIR2DL2, KIR2DL3, KIR2DS3, KIR2DP1,
KIR2DL1 and KIR3DP1) that appeared to be driven by the
KIR2DL5 and KIR2DL2/3 locus; the other was a telomeric region
(KIR2DL4, KIR3DL1, KIR3DS1, KIR2DL5, KIR2DS5, KIR2DS1,
KIR2DS4 and KIR3DL2), driven by KIR3DL1/S1.
Subdividing the KIR cluster into the two regions identified by
the LD study, simplifies the description of the haplotype structure
of the KIR genes. When we compared the frequency of
KIR Genes in Chronic HCV Infected Patients
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centromeric and telomeric motifs in the two groups, we found that
the Cen-A haplotype in homozygous was significantly more
common in SVR patients (OR = 0.63, 95% CI = 0.47–0.84; p,
0.005) and the Cen-B haplotype segment in homozygous was more
frequent in NSVR patients (OR = 2.04, 95% CI = 1.35–3.03; p,
0.001) (Table 3). Other combinations were not significant. Finally,
we analysed the association of the centromeric and telomeric KIR
haplotypes with HLA-C and HLA-B. We found a statistically
significant association of the Cen-A/A motif and HLA-C with
good treatment outcome (OR = 0.62, 95% CI = 0.45–0.84; p,
Table 1. KIR gene frequencies, KIR2DL2/3-HLA and KIR2DS2-HLA genotypes distribution in the two groups of patients.
NSVR (%)
n = 498
SVR (%)
n = 313 OR (95% CI) p
KIR2DS1 210 (42.2) 130 (41.5)
KIR2DS2 317 (63.7) 166 (53) 1.55 (1.16–2.07) ,0.005
KIR2DS3 200 (40.2) 116 (37.1)
KIR2DS4 462 (92.8) 295 (94.2)
KIR2DS5 176 (35.3) 111 (35.5)
KIR2DP1 468 (94) 302 (96.5)
KIR2DL1 466 (93.6) 302 (96.5)
KIR2DL2 323 (64.9) 172 (55) 1.51 (1.13–2.02) ,0.005
KIR2DL3 394 (79.1) 278 (88.8) 0.48 (0.32–0.72) ,0.001
KIR2DL4 498 (100) 313 (100)
KIR2DL5A 212 (42.6) 137 (43.8)
KIR2DL5B 176 (35.3) 97 (31)
KIR3DL1 461 (92.6) 290 (92.7)
KIR3DL2 498 (100) 313 (100)
KIR3DL3 498 (100) 313 (100)
KIR3DP1 498 (100) 313 (100)
KIR3DS1 211 (42.4) 136 (43.5)
KIR2DL2/KIR2DL2 104 (20.7) 35 (11.2) 2 (1.31–3.03) ,0.001
KIR2DL2/KIR2DL3 219 (44) 137 (43.8) -
KIR2DL3/KIR2DL3 175 (35.3) 141 (45) 0.66 (0.49–0.88) ,0.01
KIR2DS2-HLAC1 255 (51.2) 128 (40.9) 1.46 (1.09–1.96) ,0.01
HOMOKIR2DL2-HLAC1C1 32 (6.4) 13 (4.1) -
HOMOKIR2DL2-HLAC1C2 61 (12) 14 (4.4) 2.85 (1.56–5.26) ,0.001
HOMOKIR2DL2-HLAC2C2 11 (2.2) 8 (2.6) -
KIR2DL2/2DL3-HLAC1C1 74 (14.9) 49 (15.7) -
KIR2DL2/2DL3-HLAC1C2 95 (19) 58 (18.5) -
KIR2DL2/2DL3-HLAC2C2 50 (10.1) 30 (9.9) -
HOMOKIR2DL3-HLAC1C1 32 (6.4) 51 (16.3) 0.34 (0.21–0.54) ,0.001
HOMOKIR2DL3-HLAC1C2 91 (18.5) 60 (19.2) -
HOMOKIR2DL3-HLAC2C2 52 (10.5) 30 (9.3) -
doi:10.1371/journal.pone.0099426.t001
Table 2. Genotyping and frequencies of KIR2DL2 and KIR2DL3 alleles in relation to treatment outcome.
NSVR
(n = 146)
SVR
(n = 103) p OR (95% CI)
KIR2DL2*001 61 (41.8) 28 (27.2) ,0.05 1.92(1.11–3.31)
KIR2DL2*003 38 (26) 31 (30.1) - -
KIR2DL3*001 60 (41.1) 63 (61.2) ,0.005 0.44 (0.26–0.74)
KIR2DL3*002 74 (50.7) 45 (43.7) - -
KIR2DL3*001-HLA-C1 35 (24) 47 (45.6) ,0.001 0.37(0.22–0.65)
KIR2DL3*002-HLA-C1 60 (41.1) 37 (35.9) - -
doi:10.1371/journal.pone.0099426.t002
KIR Genes in Chronic HCV Infected Patients
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e99426
0.005). In contrast, the association of the Cen-B/B motif and
HLA-C combination was significant (OR = 2.5, 95% CI = 1.5 –
3.96; p,0.001) in relation with non-response. The Tel-HLA
combinations were not found to be associated with treatment
outcome.
Analysis of KIR genotyping and IFNL3 polymorphism
combinations
We used logic regression to examine Boolean combinations
(AND/OR/NOT) of binary covariates considered in this study, in
order to derive a model for predicting chronic HCV treatment
outcome. The final model obtained is summarised as follows.
Combinations of KIR genotyping, IFNL3 and the intersections
and unions of other factors can be expressed mathematically
(figure 3).
The measure of the importance of a variable in the response to
treatment is the frequency with which it appears independently in
all models. From the summary, the contribution of each variable
can be evaluated by the ratio of the number of times it was
included in any of the models divided by the total number of
models.
Logic regression revealed a strong association of the IFNL3
rs12979860 polymorphism in the prediction of response to
combined treatment (PPV = 55.9%) (Table 4). It was improved
when we incorporated different studies of KIR combinations in
the logic model. The inclusion of the complete analysis of KIR
genes and their combinations to the mathematical model yielded
the best result (PPV = 75.3%). The ROC curve of different logic
regression models was derived. In the best model, the area under
the curve (AUC) was 0.729 (95% CI = 0.692–0.772) (Figure 4).
In conclusion, KIR2DL3/KIR2DL3-HLA-C1/C1 and the KIR
centromeric haplotype motif (A/A genotype) are good predictors
of SVR. On the other hand, KIR2DL2/KIR2DL2-HLA-C1/C2 and
the KIR centromeric haplotype motif (B/B genotype) are
associated with a high percentage of NSVR in combination with
IFNL3 T/T. Our statistical analysis did not show any association
between KIR2DS2 and treatment outcome.
Discussion
Previous studies have described several biomarkers of treatment
response in addition to IFNL3 polymorphisms [41,42]. Other
study by our group has described the influence of KIR genes on
the progression of chronic HCV infection and treatment outcome
[29]. As well as KIR receptors, other genetic markers related to
immune response have been reported [42]. One such marker is
Figure 1. KIR genotype distribution in the study cohort. The genotypes were deduced from KIR profiles as previously described [10,33]. Note:
1ID assigned by the Allele Frequency Net Database (http://www.allelefrequencies.net)
doi:10.1371/journal.pone.0099426.g001
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PDCD1, which allowed us to develop a model for predicting the
response to conventional therapy. Combining the analysis of this
marker with IFNL3 genotyping considerably improved the
predictability of response to standard treatment established using
other parameters such as viral load or viral genotype [30].
The current models predict the treatment response of each
patient only approximately, so the search for new genetic markers
is essential if we are to be able to establish the most appropriate
therapy for each patient from the beginning of treatment [30].
As previously reported, factors such as the KIR-HLA genotype
were relevant to this response. The KIR2DL3/KIR2DL3-HLA-
C1C1 genotype was more frequent in the SVR group, while the
KIR2DL2/KIR2DL2-HLA-C1C2 genotype was more frequent in
NSVR patients. In relation with this, we found that the HLA-C*07
was associated with a good treatment response, especially in
combination with KIR2DL3. This data is interesting because this
HLA-C allele was previously associated with the HCV persistence
[43] and, more recently, with high viral load [44].
Figure 2. Pairwise D’ LD based on Cramer’s V correlation coefficient between the presence and absence of different KIR genes in
the two groups of patients (A: Non Sustained Viral Responders, NSVR; B: Sustained Viral Responders, SVR). In this approach to
assessing KIR LD, the KIR cluster genetic polymorphism is considered simply as the presence (POS) or absence (NEG) of KIR genes. Note: Several
conditions were applied for this analysis: 1) KIR3DL3, KIR3DP1, KIR2DL4 and KIR3DL2 were not included because they were present in all patients
(framework genes), 2) KIR2DL2 and KIR2DL3 were considered as alleles of the same locus, 3) KIR2DL5 was differentiated in KIR2DL5A and KIR2DL5B
because they are located at different positions, and 4) KIR2DS3 was included in the centromeric region.
doi:10.1371/journal.pone.0099426.g002
Table 3. KIR genotypes and haplotype frequencies of the studied population, and combinations of Cen and Tel haplotypes with
HLA-B and HLA-C.
NSVR (n = 498) SVR (n = 313) OR (95% CI) p
Genotype
AA 117 (23.5) 88 (28.1) NS
Bx1 381 (76.5) 225 (71.9)
Centromeric
haplotype segment
A/A 172 (34.5) 138 (44.1) 0.63 (0.47–0.84) ,0.005
A/B 222 (44.6) 140 (44.7) - NS
B/B 104 (20.9) 35 (11.2) 2.04 (1.35–3.03) ,0.001
Telomeric haplotype segment
A/A 279 (56) 133 (55.3) NS
A/B 176 (35.3) 115 (36.7)
B/B 43 (8.6) 25 (8)
Cen-HLA combinations
Cen-A/A-HLA-C1 121 (24.3) 107 (34.2) 0.62 (0.45–0.84) ,0.005
Cen-A/B-HLA-C1 172 (34.5) 110 (35.1) - NS
Cen-B/B-HLA-C1 92 (18.5) 26 (8.3) 2.5 (1.58–3.96) ,0.001
Note: 1B/B and A/B genotypes were included in this group.
Tel-HLA-C, Cen-HLA-B and Cen-HLAB combinations were not significant.
doi:10.1371/journal.pone.0099426.t003
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In order to determine specifically which allelic variant of these
genes predominates in the two groups of patients, we carried out
an oligotyping analysis of KIR2DL2 and KIR2DL3, as previously
described [35,36]. In relation to KIR2DL3, we found that the
KIR2DL3*001 allele was most common in SVR while
KIR2DL2*001 was more frequent in NSVR. In addition, the
relevance of KIR2DL3*001 to good treatment outcome is notably
greater when analysed in combination with HLA-C1. These
findings suggest these alleles are important in the response to
standard treatment, and may be associated with a weak interaction
with its ligand, as described for other alleles from KIR2DL2/3 [45].
Our results confirm the relevance of the KIR2DL2/3 alleles and
the interaction with HLA-C in the treatment outcome, which
could also be involved in the progression and chronicity of HCV
infection. With regard to KIR3DL1-HLA-Bw4, Nozawa et al
showed a significant association of this combination with SVR to
Peg-IFN/RBV in Japanese population [46]. Nonetheless, we did
not find statistical differences in our cohort, in line with previous
reports in Caucasian populations. [29,47]. This data underscore
the distinctive organisation of the human KIR locus that drives the
generation of KIR gene-content diversity in different populations
[48,49].
The human KIR locus contains highly conserved genes that are
situated in the middle (KIR3DP1 and KIR2DL4) and at the ends
(KIR3DL3 and KIR3DL2) of the cluster, creating a framework
around two regions of variability in which highly homologous KIR
genes are packed very close together in a head-to-tail configura-
tion, separated by short and highly conserved intergenic regions.
In different human populations, there is a variable balance
between A and B groups of KIR haplotypes, which seems to be
maintained by balancing selection for inhibitory and activating
functions [50]. This selection is mediated, in part, by the
interaction of inhibitory KIR with their HLA class I ligands
[51]. A relationship between KIR haplotypes and chronic HCV
infection has been demonstrated. Thus, the centromeric KIR
haplotype A was increased in patients with resolved HCV
infection compared with those who developed a chronic infection
[52].
To investigate the role of KIR genes underlying HCV action
from a different perspective, in the present study we analysed the
relationship between the KIR genotypes and haplotypes with the
response to conventional treatment. We found 35 KIR genotypes
in our cohort, all of them previously described. The biological
significance of the A/B haplotype difference means that it is worth
considering whether combinations of A and B haplotypes can
influence chronic HCV treatment outcome. The present study has
clearly confirmed that such a situation occurs in this series of
patients. We found a high frequency of homozygosity for
haplotype A in patients with SVR. When we divided this
haplotype into the A-centromeric and A-telomeric motifs, we
found that the homozygosity for Cen A/A was also more common
in SVR patients. This result is controversial because of the high
frequency of inhibitory receptors in patients with a good response.
This association may have arisen because KIR2DL3 is present in
the Cen A haplotype motif, while KIR2DL2 is part of Cen B
haplotype motif. It has also been shown that KIR2DL2 and
KIR2DL3 have different inhibitory capabilities arising from
dissimilar interactions with their ligands [45]. KIR2DL1 has the
strongest interaction with its ligands, the HLA-C2 alleles, while
KIR2DL2 associates to HLA-C1 more intensely than KIR2DL3
[53]. Bearing these data in mind, we may surmise that the stronger
interaction and therefore the stricter inhibition of NK cells would
occur in individuals homozygous for KIR2DL2 who carry the
HLA-C1/C2 genotype. Conversely, NK cells from patients who
are homozygous for KIR2DL3 and for HLA-C1 would have a
greater activation ability due to the lack of intense inhibition
arising from the interaction between KIR2DL1 and the HLA-C2
ligand. However, it should be taken into consideration that KIR-
activating receptors in the A haplotype are not reduced to
KIR2DS4, because KIR2DL4 can sometimes act as an activating
receptor [54,55].
Figure 3. Note: Cen-AA (X1), Cen-BB (X2), IFNL3-G/G (X3), IFNL3-G/T (X4), IFNL3-T/T (X5), HOMOKIR2DL3-C1C1 (X6),
HOMOKIR2DL2-C1C1 (X7), HOMOKIR2DL2-C1C2 (X8) viral load less than 400000 UI/ml (X9).
doi:10.1371/journal.pone.0099426.g003
Table 4. Prediction of treatment outcome in patients with chronic HCV infection using the proposed logic regression model.
Sensitivity Specificity PPV3 NPV4 AUC5 (95% CI)
IFNL31 51.7 74.3 55.9 71 0.658 (0.624–0.692)
KIR2DL2/3-HLA 16 95.8 70.4 64.5 0.596 (0.575–0.645)
IFNL31 + KIR2DL2/3 25 93 69 66.3 0.684 (0.642–0.720)
IFNL31 + KIR2DL2/3-HLA 13.4 97 73.7 64 0.690 (0.651–0.733)
IFNL31 + Haplotypes study 21.4 94.9 72 65.7 0.699 (0.662.0.735)
IFNL31 + KIR gene study2 21.4 95.6 75.3 65.9 0.729 (0.692–0.772)
Note:
1IFNL3 polymorphism rs12979860.
2KIR2DL2/3, KIR2DL2/3-HLA and KIR haplotype study.
3Positive predictive value.
4Negative predictive value.
5Area under the curve.
doi:10.1371/journal.pone.0099426.t004
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Suppiah et al [56], observed a significant association between
HLA groups C1 and C2 with treatment outcome and established a
logistic model to predict a failure to clear virus on therapy with
PegIFN/RBV. We did not find any association with HLA-C
groups and treatment except HLA-C*07. Nonetheless, we observed
a clear association between KIR2DL2/3 and therapy response.
Also, we studied all KIR genes to establish the different haplotypes
of these receptors, and found a statistical association with SVR.
These different results may be due to patient selection and
different study population. To assess the significance of these
results to treatment outcome, we developed a logic regression
model [37], different from Suppiah. This showed that genotyping
IFNL3 alone had a specificity of 74.3% and a positive predictive
value (PPV) of 55.9%. However, this result was improved by the
determination of KIR genes, increasing the specificity to 95.6%
and the PPV to 75.3%. Although the sensitivity decreased from
51.7% to 21.4%, these results are further evidence of the
important role that KIR receptors play in the response to
combined therapy in HCV-infected patients.
In conclusion, based on our results we propose a novel
relationship between KIR/HLA genotypes and KIR haplotypes
(A/B) in the chronicity of HCV infection. These could be used as
tools in combination with other parameters, such as the
determination of IFNL3 rs12979860, to predict treatment outcome
and in order to establish the best cost-effective treatment between
the classical regimen and the new arrival therapies. Further
research is required to determine the molecular mechanisms
involved in this process.
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